Single and repeated intra-articular injections in the tarsocrural joint with allogeneic and autologous equine bone marrow-derived mesenchymal stem cells are safe, but did not reduce acute inflammation in an experimental interleukin-1β model of synovitis.
Authors: Colbath Aimée C, Dow Steven W, Hopkins Leone S, Phillips Jennifer N, McIlwraith C Wayne, Goodrich Laurie R
Journal: Equine veterinary journal
Summary
# Editorial Summary Mesenchymal stem cell (MSC) therapy has gained traction in equine joint disease management, yet the comparative efficacy of allogeneic versus autologous bone marrow-derived MSCs—particularly regarding their purported anti-inflammatory capacity—remained poorly characterised in controlled conditions. Researchers induced acute synovitis in the tarsocrural joint of horses using interleukin-1β and subsequently administered either allogeneic MSCs, autologous MSCs, or vehicle control via single or repeated intra-articular injections, monitoring inflammatory markers (synovial fluid cytology, cytokine profiles, and clinical parameters) over 14 days. Both cell types proved safe with no adverse local or systemic reactions, yet neither allogeneic nor autologous BMDMSCs demonstrated meaningful suppression of IL-1β-induced inflammation compared to untreated controls—synovial fluid interleukin-6 and other inflammatory mediators remained elevated regardless of MSC treatment. These findings suggest that whilst MSC administration appears well-tolerated, practitioners should reconsider expectations around acute anti-inflammatory efficacy in naturally occurring joint disease, and further research into optimal dosing, timing, and cell preparation protocols is warranted before confidently attributing clinical improvements to MSC-mediated immunomodulation rather than other concurrent interventions or natural disease resolution.
Read the full abstract on PubMed
Practical Takeaways
- •While stem cell injections are safe, their anti-inflammatory effects may not be effective in acute inflammatory conditions like synovitis induced by IL-1β
- •Allogeneic stem cells present a practical alternative to autologous cells given equivalent safety profiles and easier logistics for clinical use
- •Practitioners should consider that stem cell therapy effectiveness may depend on the inflammatory stage and underlying pathology, and may not be suitable as a primary treatment for acute joint inflammation
Key Findings
- •Both allogeneic and autologous BMDMSCs were safe when administered as single or repeated intra-articular injections in the tarsocrural joint
- •Neither allogeneic nor autologous BMDMSCs reduced acute inflammation in the IL-1β-induced synovitis model
- •Allogeneic BMDMSCs offer clinical and practical advantages over autologous cells despite equivalent efficacy in this acute inflammation model